Virus-Like Particles as Preventive and Therapeutic Cancer Vaccines

Research output: Contribution to journalReview articlepeer-review


Virus-like particles (VLPs) are self-assembled viral protein complexes that mimic the native virus structure without being infectious. VLPs, similarly to wild type viruses, are able to effi-ciently target and activate dendritic cells (DCs) triggering the B and T cell immunities. Therefore, VLPs hold great promise for the development of effective and affordable vaccines in infectious diseases and cancers. Vaccine formulations based on VLPs, compared to other nanoparticles, have the advantage of incorporating multiple antigens derived from different proteins. Moreover, such antigens can be functionalized by chemical modifications without affecting the structural conformation or the antigenicity. This review summarizes the current status of preventive and therapeutic VLP-based vaccines developed against human oncoviruses as well as cancers.

Original languageEnglish
Article number227
Issue number2
Publication statusPublished - Feb 2022


  • Antigen delivery
  • Cancer vaccine
  • EBV
  • Epstein–Barr virus
  • HBV
  • Hepatitis B
  • HHV8
  • HPV
  • Human herpesvirus type 8
  • Human papillomavirus
  • Virus-like particles
  • VLPs

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Virus-Like Particles as Preventive and Therapeutic Cancer Vaccines'. Together they form a unique fingerprint.

Cite this